Skip to main content
Premium Trial:

Request an Annual Quote

Calando Pharmaceuticals, new Arrowhead Subsidiary, to Commercialize Therapeutic RNAi Delivery Technologies

NEW YORK, Feb. 22 (GenomeWeb News) - Arrowhead Research has formed a new subsidiary, Calando Pharmaceuticals, which plans to commercialize technologies for the therapeutic use of RNA interference, the Pasadena, Calif.-based company said today.

 

Calando, majority-owned by nanotechnology company Arrowhead, intends to develop non-viral RNAi delivery technologies licensed from the California Institute of Technology for therapeutic purposes. Caltech will receive an equity stake in exchange for the license.

 

Apart from Arrowhead, founders of Calando include Mark Davis, a professor of chemical engineering at Caltech; John Rossi, a molecular geneticist at the City of Hope's Beckman Research Institute; Matt Vincent, a partner of law firm Ropes & Gray; and John Petrovich, who will be Calando's CEO.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.